Terminated PHASE2 INTERVENTIONAL 1-arm NCT00525161

Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer

A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (Nexavar) to Existing Endocrine Therapy in Patients With Advanced Breast Cancer

Sponsor: Bayer

Conditions Breast Cancer

Interventions sorafenib

Updated 7 times since 2017 Last updated: Jan 12, 2015 Started: Oct 31, 2007 Primary completion: Jan 31, 2013 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual and loss of funding

Other terminated trials from Bayer

See all terminations from Bayer

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

Listed as NCT00525161, this PHASE2 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by Bayer, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Suleiman Massarweh

Data source: University of Kentucky

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lexington, United States